Physiological and pharmacological roles of ABCG2 (BCRP): Recent findings in Abcg2 knockout mice

被引:182
作者
Vlaming, Maria L. H. [1 ]
Lagas, Jurjen S. [1 ]
Schinkel, Alfred H. [1 ]
机构
[1] Netherlands Canc Inst, Div Expt Therapy, NL-1066 CX Amsterdam, Netherlands
关键词
BCRP/Bcrp1; Blood-brain barrier; Blood-placental barrier; Blood-testis barrier; Blood-retinal barrier; Mammary gland; Vitamin transport; Harderian gland; Porphyrins; Phytoestrogens; CANCER RESISTANCE PROTEIN; BLOOD-BRAIN-BARRIER; LIMITS FETAL DISTRIBUTION; P-GLYCOPROTEIN; MILK SECRETION; IN-VIVO; EFFLUX TRANSPORTERS; PROTOPORPHYRIN-IX; DRUG TRANSPORTERS; HARDERIAN-GLAND;
D O I
10.1016/j.addr.2008.08.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The multidrug transporter ABCG2 (BCRP/MXR/ABCP) can actively extrude a broad range of endogenous and exogenous substrates across biological membranes. ABCG2 limits oral availability and mediates hepatobiliary and renal excretion of its substrates, and thus influences the pharmacokinetics of many drugs. Recent work. relying mainly on the use of Abcg2(-/-) mice, has revealed important contributions of ABCG2 to the blood-brain, blood-testis and blood-fetal barriers. Together, these functions indicate a primary biological role of ABCG2 in protecting the organism from a range of xenobiotics. In addition, several other physiological functions of ABCG2 have been observed. including extrusion of porphyrins and/or porphyrin conjugates from hematopoietic cells, liver and harderian gland, as well as secretion of vitamin B-2 (riboflavin) and possibly other vitamins (biotin, vitamin K) into breast milk. However, the physiological significance of these processes has been difficult to establish, indicating that there is still a lot to learn about this intriguing protein. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:14 / 25
页数:12
相关论文
共 67 条
  • [41] The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin
    Merino, G
    Jonker, JW
    Wagenaar, E
    van Herwaarden, AE
    Schinkel, AH
    [J]. MOLECULAR PHARMACOLOGY, 2005, 67 (05) : 1758 - 1764
  • [42] The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib
    Oostendorp, Roos L.
    Buckle, Tessa
    Beijnen, Jos H.
    van Tellingen, Olaf
    Schellens, Jan H. M.
    [J]. INVESTIGATIONAL NEW DRUGS, 2009, 27 (01) : 31 - 40
  • [43] PAYNE AP, 1994, J ANAT, V185, P1
  • [44] Polgar O, 2008, EXPERT OPIN DRUG MET, V4, P1, DOI [10.1517/17425255.4.1.1, 10.1517/17425255.4.1.1 ]
  • [45] The role of placental breast cancer resistance protein in the efflux of glyburide across the human placenta
    Pollex, E.
    Lubetsky, A.
    Koren, G.
    [J]. PLACENTA, 2008, 29 (08) : 743 - 747
  • [46] Powers HJ, 2003, AM J CLIN NUTR, V77, P1352
  • [47] Interaction of enrofloxacin with breast cancer resistance protein (BCRP/ABCG2): influence of flavonoids and role in milk secretion in sheep
    Pulido, Mivis M.
    Molina, Antonio J.
    Merino, Gracia
    Mendoza, Gracia
    Prieto, Julio G.
    Alvarez, Ana I.
    [J]. JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2006, 29 (04) : 279 - 287
  • [48] Biotin: the forgotten vitamin
    Said, HM
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 2002, 75 (02) : 179 - 180
  • [49] P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs
    Schinkel, AH
    Wagenaar, E
    Mol, CAAM
    vanDeemter, L
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (11) : 2517 - 2524
  • [50] DISRUPTION OF THE MOUSE MDR1A P-GLYCOPROTEIN GENE LEADS TO A DEFICIENCY IN THE BLOOD-BRAIN-BARRIER AND TO INCREASED SENSITIVITY TO DRUGS
    SCHINKEL, AH
    SMIT, JJM
    VANTELLINGEN, O
    BEIJNEN, JH
    WAGENAAR, E
    VANDEEMTER, L
    MOL, CAAM
    VANDERVALK, MA
    ROBANUSMAANDAG, EC
    TERIELE, HPJ
    BERNS, AJM
    BORST, P
    [J]. CELL, 1994, 77 (04) : 491 - 502